WO2014059279A3 - Materials and methods useful to treat neuroblastomas and pheochromocytomas - Google Patents

Materials and methods useful to treat neuroblastomas and pheochromocytomas Download PDF

Info

Publication number
WO2014059279A3
WO2014059279A3 PCT/US2013/064546 US2013064546W WO2014059279A3 WO 2014059279 A3 WO2014059279 A3 WO 2014059279A3 US 2013064546 W US2013064546 W US 2013064546W WO 2014059279 A3 WO2014059279 A3 WO 2014059279A3
Authority
WO
WIPO (PCT)
Prior art keywords
tianeptine
pheochromocytomas
neuroblastomas
treat
materials
Prior art date
Application number
PCT/US2013/064546
Other languages
French (fr)
Other versions
WO2014059279A2 (en
Inventor
Joshua J. PARK
Kenneth Hensley
Original Assignee
The University Of Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Toledo filed Critical The University Of Toledo
Publication of WO2014059279A2 publication Critical patent/WO2014059279A2/en
Publication of WO2014059279A3 publication Critical patent/WO2014059279A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

Methods for affecting one or more of: proliferation, migration and invasion of tumor cells are described. One method includes contacting the tumor cell with an effective amount of a composition such as tianeptine. Described herein are results showing that tianeptine causes apoptosis by increasing microtubule bundling in neuroblastoma and pheochromocytoma cells. In addition, tianeptine blocks growth of neuroblastoma and pheochromocytoma by inducing specific and rapid degradation of cytoplasmic dynein, a microtubule motor protein that arranges the mitotic spindles during mitosis.
PCT/US2013/064546 2012-10-13 2013-10-11 Materials and methods useful to treat neuroblastomas and pheochromocytomas WO2014059279A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713520P 2012-10-13 2012-10-13
US61/713,520 2012-10-13

Publications (2)

Publication Number Publication Date
WO2014059279A2 WO2014059279A2 (en) 2014-04-17
WO2014059279A3 true WO2014059279A3 (en) 2014-06-05

Family

ID=50478073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/064546 WO2014059279A2 (en) 2012-10-13 2013-10-11 Materials and methods useful to treat neuroblastomas and pheochromocytomas

Country Status (1)

Country Link
WO (1) WO2014059279A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031648A1 (en) * 1999-12-07 2005-02-10 Allergan, Inc. Methods for treating diverse cancers
US20060276527A1 (en) * 2003-01-17 2006-12-07 Thresold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer
WO2009101012A1 (en) * 2008-02-13 2009-08-20 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Methods for treating and preventing brain tumors based on bone morphogenetic proteins
US20110117627A1 (en) * 2008-07-10 2011-05-19 The Board Of Trustees Of The University Of Illinois Regulation of apoptosis by neural specific splice variants of ig20
WO2012109705A1 (en) * 2011-02-15 2012-08-23 Clean Teq Limited Method and system for extraction of uranium using an ion-exchange resin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031648A1 (en) * 1999-12-07 2005-02-10 Allergan, Inc. Methods for treating diverse cancers
US20060276527A1 (en) * 2003-01-17 2006-12-07 Thresold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer
WO2009101012A1 (en) * 2008-02-13 2009-08-20 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Methods for treating and preventing brain tumors based on bone morphogenetic proteins
US20110117627A1 (en) * 2008-07-10 2011-05-19 The Board Of Trustees Of The University Of Illinois Regulation of apoptosis by neural specific splice variants of ig20
WO2012109705A1 (en) * 2011-02-15 2012-08-23 Clean Teq Limited Method and system for extraction of uranium using an ion-exchange resin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Annual Report on Technology Transfer", ADVANCING INNOVATION AND ENTREPRENEURSHIP, 2011, UNIVERSITY OF TOLEDO, pages 1 - 4 *
LI ET AL.: "Induction of apoptosis in pheochromocytoma (PC12) cells exposed to eicosapentaenoic acid in vitro.", INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS, vol. 42, August 2005 (2005-08-01), pages 222 - 229 *
MATERIALS AND METHODS FOR TREATING NEUROBLASTOMA AND MALIGNANT PHEOCHROM., 23 October 2012 (2012-10-23), UNIVERSITY OF TOLEDO, pages 1 - 2 *

Also Published As

Publication number Publication date
WO2014059279A2 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
MX2013005673A (en) Nk cell modulating treatments and methods for treatment of hematological malignancies.
EP3611173A4 (en) Organic light emitting element and composition for organic material layer in organic light emitting element
EP3701041A4 (en) Methods and compositions for treating diseases associated with exhausted t cells
NZ709215A (en) Compositions comprising anti-cd38 antibodies and lenalidomide
EP3615010A4 (en) Methods for treating dravet syndrome
EP3092063A4 (en) Treated mixed matrix polymeric membranes
EP3471990A4 (en) Systems, methods and devices for induction-based power harvesting in battery-powered vehicles
TWI562168B (en) Composition for solar cell electrodes and electrode fabricated using the same
EP3460890A4 (en) Cell electrode, composition for cell electrode catalyst layer, and cell
EP3582856A4 (en) Compositions and methods for activating nk cells
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
AU2014353091A8 (en) Porous SIOx materials for improvement in SIOx switching device performances
EP3512012A4 (en) Conductive composition for electrodes, and electrode and battery using same
EP3327833A4 (en) Negative electrode active material having improved output characteristics and electrode for electrochemical device, containing negative electrode active material
EP3118891A4 (en) Composition and organic thin-film transistor using same
EP3466996A4 (en) Organic silicon compound, and additive for rubber and rubber composition using same
MX2016005507A (en) Eluting matrix and uses thereof.
EP3232114A4 (en) Electrochemical light emitting cell, composition for forming light emitting layer of electrochemical light emitting cell, and ionic compound for light emitting layer of electrochemical light emitting cell
EP3861707A4 (en) Distributing content to render at vehicles
EP3236518A4 (en) Negative-electrode active material for electric device, and electric device using same
WO2013162933A3 (en) Active halogen antimicrobial composition and method of use
EP3101037A4 (en) Modified conjugated diene-based polymer, preparation method therefor, and rubber composition containing same
EP3088565A4 (en) Substrate treated with color development, and substrate color development treatment method for same
BR112015020783A2 (en) microlamellar electrode cell and its use
EP3236520A4 (en) Negative-electrode active material for electrical device, and electrical device using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13844878

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13844878

Country of ref document: EP

Kind code of ref document: A2